TREATMENT OF OBSESSIVE COMPULSIVE DISORDER

Abstract: A method for the treatment of OCD in a mammal by administering to the mammal an effective amount of 1,7,7-trimethylbicyclo[2.2.1]heptane derivative of Formula (I) wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.

Description: TREATMENT OF OBSESSIVE COMPULSIVE DISORDER FIELD OF THE INVENTION The present invention relates in general to a method for the treatment of obsessive compulsive disorder in a mammal. More particularly, this invention relates to a method for the treatment of obsessive compulsive disorder in a mammal by administering to the mammal an effective amount of l,7,7-trimethylbicyclo[2.2.1]heptane derivative of Formula I wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof. Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realised and attained by means of the elements and combinations particularly pointed out in the appended claims. BACKGROUND OF THE INVENTION Obsessive Compulsive Disorder (OCD) is a chronic condition associated with obsessional and compulsive features, such as repetitive compulsive behaviour performed in a ritualistic manner and/or recurrent, intrusive, obsessional thoughts. A patient may suffer from OCD as a single disorder, or OCD may be accompanied by an affective disorder, such as depression or other anxiety disorders, such as Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD) or agarophobia. The active ingredients of this invention, (lR,2S,4R)-(-)- 2-phenyl-2- (dimethylaminoethoxy)-l,7,7-trimethyl-bicyclo[2.2.1]heptane, known as deramciclane, and (lR,2S,4R)-(-)- 2-phenyl-2-(methylaminoethoxy)-l,7,7-trimethyl- bicyclo[2.2.1]heptane, and their pharmaceutically acceptable acid addition salts with inorganic and organic acids generally used for the purpose, fall within the disclosures of U.S. Patent No. 4,342,762 and International Patent Application No. WO 98/17230, respectively, which are both incorporated herein by reference. These compounds are selective serotonin 5HT2A- and/or 5HT2C-receptor antagonists. They have shown anxiolytic-like effects in animal test models. DESCRIPTION OF THE INVENTION Applicants have surprisingly discovered that the compounds of formula (I) do reduce one or several symptoms of OCD in a mammal. Accordingly, an object of the present invention is a method for treating OCD in a mammal by administering to the mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Another object of the invention is a method for treating OCD in a mammal by administering to the mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof together with a benzodiazepine or an antidepressant. The antidepressant may be a tricyclic antidepressant, such as clomipramine, a SSRJ, such as fluoxetine or paroxetine, or a SNRI, such as venlafaxine. For the purposes of this disclosure and claims the term "treatment" is relating to treatment in order to cure or alleviate the disease or its symptoms, and to treatment in order to prevent the development or the exacerbation of the disease or its symptoms. Pharmaceutically acceptable salts of the compound of Formula (I) can be formed with inorganic acids, e.g. hydrohalogenic acid such as hydrochlorid acid or hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid, or organic acids e.g., tartaric acid, succinic acid, malic acid, maleic acid, fumaric acid, citric acid, or lactic acid. Salt with fumaric acid is preferred. Pharmaceutical compositions containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient include the usual oral dosage forms, such as tablets, capsules, and liquid preparations. In oral dosage forms, the active incredient can be mixed with suitable pharmaceutically acceptable excipients, such as starch, lactose, sucrose and magnesium stearate, in accordance with conventional pharmaceutical practice. The precise amount of the drug to be administered to a mammal for treating or preveting OCD is dependent on numerous factors known to one skilled in the art, such as the compund to be administered, the general condition of the patient, the condition to be treated etc. For example, the usual recommended oral daily dose of deramciclane would be about 5-150 mg, preferably 30-60 mg. The invention will be further clarified by the following example, which is intended to be purely exemplary of the invention. EXAMPLE The efficacy of deramciclane in the treatment of OCD, is illustrated with two patients having obsessive-compulsive symptoms. These patients received one 15mg tablet of deramciclane twice daily (=30mg/day) for an eight- week active treatment period. RESULTS As assessed by the responsible physician, the obsessive-compulsive symptoms were reduced in a clinically significant way during the 8 week treatment period. Although the invention has been illustrated by the preceding example, it is not to be construed as being limited to the materials employed therein. Rather, the invention is directed to the generic area as herein disclosed. Various modifications and embodiments thereof can be made without departing from the spirit or scope thereof.

Claims: CLAIMS: 1. Use of a compound of Formula (I) wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating obsessive compulsive disorder. 2. The use of claim 1, wherein Obsessive Compulsive Disorder is accompanied with an anxiety disorder. 3. The use of claim 2, wherein the anxiety disorder is Generalized Anxiety Disorder. 4. The use of claim 2, wherein the anxiety disorder is Social Anxiety Disorder. 5. The use of claim 2, wherein the anxiety disorder is Panic Disorder. 6. The use of claim 2, wherein the anxiety disorder is agoraphobia. 7. The use of any one of claim 1, wherein the mammal is human. 8. The use of claim 1, wherein the compound is deramciclane or a pharmaceutically acceptable salt thereof. 9. The use of claim 1, wherein about 5-150 mg/day of the compound of Formula (I) or pharmaceutically acceptable salt thereof is administered. 10. The use of claim 9, wherein about 10-60 mg/day of the compound of Formula (I) or pharmaceutically acceptable salt thereof is administered. 11. The use of claim 10, wherein about 30 mg/day of the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered. 12. The use of claim 1 , further comprising administering a benzodiazepine together with the compound of Formula (I) or pharmaceutically acceptable salt thereof. 13. The use of claim 1, further comprising administering an antidepressant together with the compound of Formula (I) or pharmaceutically acceptable salt thereof

Inventors: JASKARI MARTTI, LEHTONEN LEENA, MAEKI-IKOLA OUTI, ROURU JUHA, WALLIN MATTI, JASKARI, MARTTI, LEHTONEN, LEENA, MAEKI-IKOLA, OUTI, ROURU, JUHA, WALLIN, MATTI
Applicants: JASKARI MARTTI, LEHTONEN LEENA, MAEKI IKOLA OUTI, ORION CORP, ROURU JUHA, WALLIN MATTI, JASKARI, MARTTI, LEHTONEN, LEENA, MAEKI-IKOLA, OUTI, ORION CORPORATION, ROURU, JUHA, WALLIN, MATTI
Application year: 2001
Main classification: A61K31
IPC codes: A61K31, A61P25